Combination Gene Therapy and Th1Th2 Therapy

我们的工作重点是使用慢病毒载体将基因转移到雷帕霉素抗性T细胞。 使用这种方法，可以诱导给定培养物中的大多数T细胞表达新基因。 我们还开发了动物模型来测试这些免疫基因治疗策略的体内效果。 这种模型包括肿瘤，也评估移植物抗宿主病，这仍然是异基因造血干细胞移植后的主要并发症。为了促进该项目的实施，我们与Lentigen公司达成了一项合作研究协议，以开发临床方案，重点是慢病毒递送自杀基因。相关癌症部位：非霍奇金淋巴瘤，白血病。 相关研究领域：基因治疗，骨髓移植，器官移植研究，联合治疗模式，血液学/淋巴学。

We have focused our efforts on the use of lentiviral vectors to transfer genes to the rapamycin-resistant T cells. Using this approach, the majority of T cells in a given culture can be induced to express the new gene. We have also developed animal models to test the in vivo effect of these immuno-gene therapy strategies. Such models incorporate tumors and also evaluate graft-versus-host disease, which remains the main complication after allogeneic hematopoietic stem cell transplantation. To facilitate implementation of this project, we have entered into a cooperative research agreement with Lentigen Corporation to develop clinical protocols focusing on lentiviral delivery of suicide genes.Relevant cancer sites: Non-Hodgkins Lymphoma, Leukemia. Relevant Research Areas: Gene Therapy, Bone Marrow Transplantation, Organ Transplantation Research, Combined Treatment Modalities, Hematology/Lymph.